FDA Inspection
Juno Therapeutics, Inc.Juno Therapeutics, Inc. – FDA Inspection, Sep 20, 2023
Record Details
This FDA Inspection record concerns Juno Therapeutics, Inc., with an inspection on September 20, 2023, issued by the Center for Drug Evaluation and Research, covering drugs.
View Company Profile
ID · 788615a3-a24c-4b20-a025-fd3cb9aeea6c
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1218201
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
- Outcome
- Form 483 issued
FDA Citations
6- 21 CFR 211.113(b)Procedures for sterile drug products
- 21 CFR 211.22(d)Procedures not in writing, fully followed
- 21 CFR 211.67(b)Written procedures not established/followed
- 21 CFR 211.113(b)Procedures for sterile drug products
- 21 CFR 211.22(d)Procedures not in writing, fully followed
- 21 CFR 211.67(b)Written procedures not established/followed
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Juno Therapeutics, Inc.
2| Date | Classification | Office | Project area |
|---|---|---|---|
| November 4, 2025 | Not classified | Seattle District Office | |
| September 24, 2024 | NAI | Center for Biologics Evaluation and Research | Human Cellular, Tissue, and Gene Therapies |
Other documents for Juno Therapeutics, Inc.
- FDA Inspection 1287586 - 2025-11-04
- FDA Inspection 1229984 - 2024-09-24
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.